| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways.
|
Nat Rev Clin Oncol
|
2010
|
4.22
|
|
2
|
Design issues of randomized phase II trials and a proposal for phase II screening trials.
|
J Clin Oncol
|
2005
|
3.36
|
|
3
|
Heat shock protein 90.
|
Curr Opin Oncol
|
2003
|
2.73
|
|
4
|
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer.
|
Clin Cancer Res
|
2007
|
2.50
|
|
5
|
Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation.
|
Proc Natl Acad Sci U S A
|
2013
|
2.14
|
|
6
|
Cediranib for metastatic alveolar soft part sarcoma.
|
J Clin Oncol
|
2013
|
1.99
|
|
7
|
Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers.
|
Clin Cancer Res
|
2005
|
1.97
|
|
8
|
Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers.
|
Clin Cancer Res
|
2007
|
1.92
|
|
9
|
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group.
|
J Clin Oncol
|
2008
|
1.87
|
|
10
|
The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee.
|
Clin Cancer Res
|
2010
|
1.85
|
|
11
|
Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study.
|
Clin Cancer Res
|
2007
|
1.80
|
|
12
|
Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors.
|
J Natl Cancer Inst
|
2010
|
1.73
|
|
13
|
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group.
|
J Clin Oncol
|
2008
|
1.69
|
|
14
|
A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a Children's Oncology Group study.
|
Clin Cancer Res
|
2007
|
1.61
|
|
15
|
Breast cancer growth and metastasis: interplay between cancer stem cells, embryonic signaling pathways and epithelial-to-mesenchymal transition.
|
Breast Cancer Res
|
2011
|
1.57
|
|
16
|
A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer.
|
Clin Cancer Res
|
2008
|
1.56
|
|
17
|
Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors.
|
J Clin Oncol
|
2010
|
1.38
|
|
18
|
Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies.
|
Eur J Cancer
|
2009
|
1.36
|
|
19
|
Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study.
|
J Clin Oncol
|
2010
|
1.15
|
|
20
|
Controversies in cancer stem cells: targeting embryonic signaling pathways.
|
Clin Cancer Res
|
2010
|
1.12
|
|
21
|
Developing standards for breakthrough therapy designation in oncology.
|
Clin Cancer Res
|
2013
|
1.09
|
|
22
|
Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097).
|
J Thorac Oncol
|
2010
|
1.07
|
|
23
|
A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies.
|
Clin Cancer Res
|
2008
|
1.04
|
|
24
|
A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: a Children's Oncology Group study.
|
Pediatr Blood Cancer
|
2010
|
1.04
|
|
25
|
A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575).
|
Invest New Drugs
|
2013
|
0.99
|
|
26
|
Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors.
|
Invest New Drugs
|
2010
|
0.98
|
|
27
|
Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study.
|
Cancer Chemother Pharmacol
|
2011
|
0.96
|
|
28
|
A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors.
|
Invest New Drugs
|
2013
|
0.95
|
|
29
|
Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia.
|
Haematologica
|
2011
|
0.92
|
|
30
|
A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma.
|
Gynecol Oncol
|
2011
|
0.89
|
|
31
|
A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors.
|
Cancer Chemother Pharmacol
|
2011
|
0.89
|
|
32
|
Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study.
|
Clin Cancer Res
|
2013
|
0.87
|
|
33
|
A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortium.
|
Invest New Drugs
|
2013
|
0.84
|
|
34
|
Metabolic profile of XK469 (2(R)-[4-(7-chloro-2-quinoxalinyl)oxyphenoxy]-propionic acid; NSC698215) in patients and in vitro: low potential for active or toxic metabolites or for drug-drug interactions.
|
Cancer Chemother Pharmacol
|
2005
|
0.84
|
|
35
|
Evaluation of plasma insulin-like growth factor binding protein 2 and Her-2 extracellular domain as biomarkers for 17-allylamino-17-demethoxygeldanamycin treatment of adult patients with advanced solid tumors.
|
Clin Cancer Res
|
2007
|
0.84
|
|
36
|
A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors.
|
Invest New Drugs
|
2012
|
0.84
|
|
37
|
Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors.
|
Am Heart J
|
2012
|
0.83
|
|
38
|
Sunitinib in relapsed or refractory diffuse large B-cell lymphoma: a clinical and pharmacodynamic phase II multicenter study of the NCIC Clinical Trials Group.
|
Leuk Lymphoma
|
2011
|
0.82
|
|
39
|
First-in-human phase 0 trial of oral 5-iodo-2-pyrimidinone-2'-deoxyribose in patients with advanced malignancies.
|
Clin Cancer Res
|
2013
|
0.81
|
|
40
|
A multi-center phase Ib study of oxaliplatin (NSC#266046) in combination with fluorouracil and leucovorin in pediatric patients with advanced solid tumors.
|
Pediatr Blood Cancer
|
2012
|
0.81
|
|
41
|
Profound hair and skin hypopigmentation in an African American woman treated with the multi-targeted tyrosine kinase inhibitor pazopanib.
|
J Clin Oncol
|
2010
|
0.81
|
|
42
|
The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors.
|
Cancer Chemother Pharmacol
|
2010
|
0.81
|
|
43
|
A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients.
|
Invest New Drugs
|
2014
|
0.80
|
|
44
|
Proceedings of the Oxygen Homeostasis/Hypoxia Meeting.
|
Cancer Res
|
2004
|
0.80
|
|
45
|
Molecular conversations and the development of the hair follicle and basal cell carcinoma.
|
Cancer Prev Res (Phila)
|
2010
|
0.80
|
|
46
|
The prognostic significance of P-glycoprotein, multidrug resistance-related protein 1 and lung resistance protein in pediatric acute lymphoblastic leukemia: a retrospective study of 295 newly diagnosed patients by the Children's Oncology Group.
|
Leuk Lymphoma
|
2005
|
0.79
|
|
47
|
Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine.
|
Cancer Chemother Pharmacol
|
2008
|
0.78
|
|
48
|
Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers.
|
Cancer Chemother Pharmacol
|
2005
|
0.78
|
|
49
|
A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms.
|
Haematologica
|
2013
|
0.77
|
|
50
|
A dose escalation and pharmacodynamic study of triapine and radiation in patients with locally advanced pancreas cancer.
|
Int J Radiat Oncol Biol Phys
|
2012
|
0.77
|
|
51
|
Theoretical and practical application of traditional and accelerated titration Phase I clinical trial designs: the Wayne State University experience.
|
J Biopharm Stat
|
2009
|
0.75
|
|
52
|
A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma.
|
Cancer Chemother Pharmacol
|
2008
|
0.75
|
|
53
|
Challenges and Opportunities for Immunotherapies in Gynecologic Cancers.
|
Oncology (Williston Park)
|
2016
|
0.75
|
|
54
|
Similar efficacy for phase I trials in comparison with DTIC for advanced malignant melanoma: an analysis of melanoma outcomes in CTEP-sponsored phase I trials 1995-2011.
|
Melanoma Res
|
2013
|
0.75
|
|
55
|
Sunitinib malate in patients with intermediate-2 or high-risk myelodysplastic syndrome or chronic myelomonocytic leukemia.
|
Leuk Lymphoma
|
2014
|
0.75
|